KANGSTEM BIOTECH CO., LTD. Logo

KANGSTEM BIOTECH CO., LTD.

Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.

217730 | KO

Overview

Corporate Details

ISIN(s):
KR7217730001
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로 522 홍우빌딩 9층, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kangstem Biotech Co., Ltd. is a biopharmaceutical company dedicated to the research and development of stem cell therapeutics for rare and incurable diseases. The company's core mission is to address unmet medical needs through innovative, next-generation biopharmaceuticals. In addition to its therapeutic pipeline, Kangstem Biotech operates several key business segments. These include the production and commercialization of specialized stem cell culture media and mediums, noted for their efficacy in mesenchymal stem cell proliferation. The company also provides a proprietary cell freezing and thawing platform and offers Contract Development and Manufacturing Organization (CDMO) services, leveraging its expertise in cell-based technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 159.6 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.9 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.9 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 85.3 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-08-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 7.8 KB
2025-08-25 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 158.0 KB

Automate Your Workflow. Get a real-time feed of all KANGSTEM BIOTECH CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KANGSTEM BIOTECH CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KANGSTEM BIOTECH CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.